Patients with a common form of kidney cancer called clear cell renal cell carcinoma (ccRCC) who have a high risk of recurrence after surgery showed significantly improved disease-free survival when treated with an oral combination ...
Mar 2, 2026
0
7
This local biotech says it has found a way to trick cancer cells into destroying themselves with its molecular glue. Now it's putting that claim to the test. After attracting global attention from researchers and billions ...
Feb 7, 2026
0
13
Among modern cancer therapies, immune checkpoint inhibitors (ICI) are among the most successful treatment methods. These antibodies activate the immune system and enable T cells to detect and destroy tumor cells.
Jan 15, 2026
0
11
According to a Phase I study led by researchers at The University of Texas MD Anderson Cancer Center, published in Nature Medicine, the novel monoclonal antibody linavonkibart has demonstrated the potential to overcome treatment ...
Jan 13, 2026
0
18
KEYMAKER-U03 is an international, multicenter, open-label, Phase I/II umbrella trial evaluating experimental combinations of pembrolizumab-based immunotherapy and targeted treatments for advanced clear cell renal cell carcinoma ...
Oct 21, 2025
0
25
Results from a trial led by researchers from The University of Texas MD Anderson Cancer Center showed that a targeted therapy combination improved outcomes for patients with metastatic clear-cell renal carcinoma (ccRCC)—a ...
Oct 20, 2025
0
19
A simple urine test that can assess the risk of kidney cancer recurrence at an early stage could spare patients from frequent X-ray examinations and thus reduce the associated radiation, anxiety and costs.
Sep 1, 2025
0
18
A study led by Roswell Park Comprehensive Cancer Center helps explain why a rare and hyper-aggressive subtype of kidney cancer is susceptible to immunotherapy—information that helped researchers create a first-of-its-kind ...
Aug 8, 2025
0
41
A two-drug combination for treating advanced kidney cancer has shown sustained and durable clinical benefit in more than five years of follow-up, according to a study published in Nature Medicine.
Aug 1, 2025
0
36
Scientists have discovered tumors can tap a nontraditional pathway to acquire lipoproteins—molecules that transport fat in blood—which enriches cancer cells with an antioxidant shield to survive stress, according to new research ...
Jun 12, 2025
0
29
